Amgen (AMGN)
NASDAQ:AMGN

Amgen (AMGN) Stock Forecast & Price Target

4,631 Followers
See the Price Targets and Ratings of:

AMGN Analyst Ratings

Hold
15Ratings
4 Buy
7 Hold
4 Sell
Based on 15 analysts giving stock ratings to
Amgen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AMGN Stock 12 Months Forecast

Average Price Target

$259.57
▼(-9.37% Downside)
Based on 15 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is $259.57 with a high forecast of $325.00 and a low forecast of $185.00. The average price target represents a -9.37% change from the last price of $286.40.
Highest Price Target$325.00Average Price Target$259.57Lowest Price Target$185.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Piper Sandler
$278.00
Buy
-2.93%
Downside
Reiterated
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $278
Barclays
$234.00
Sell
-18.30%
Downside
Downgraded
Stocks making the biggest moves midday: Wynn Resorts, TuSimple, Newell Brands, First Solar and moreBarclays downgraded Amgen to underweight from equal weight, saying investor enthusiasm ahead of an obesity drug update next week may be overdone.
Robert W. Baird
$185.00
Sell
-35.41%
Downside
Reiterated
Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), BioMarin Pharmaceutical (NASDAQ: BMRN) and Teladoc (NYSE: TDOC)
J.P. Morgan
$265.00
Hold
-7.47%
Downside
Reiterated
Amgen (AMGN) PT Raised to $265 at JPMorganJPMorgan analyst Chris Schott raised the price target on Amgen (NASDAQ: AMGN) to $265.00 (from $227.00) while maintaining a Neutral rating.
Daiwa
$252.00
Buy
-12.01%
Downside
Reiterated
Amgen (AMGN) PT Raised to $252 at Daiwa SecuritiesDaiwa Securities analyst Narumi Nakagiri raised the price target on Amgen (NASDAQ: AMGN) to $252.00 (from $235.00) while maintaining a Buy (2) rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AMGN Financial Forecast

AMGN Earnings Forecast
Next quarter’s earnings estimate for AMGN is $4.09 with a range of $3.91 to $4.29. The previous quarter’s EPS was $4.70. AMGN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
Next quarter’s earnings estimate for AMGN is $4.09 with a range of $3.91 to $4.29. The previous quarter’s EPS was $4.70. AMGN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
AMGN Sales Forecast
Next quarter’s sales forecast for AMGN is $6.76B with a range of $6.63B to $6.91B. The previous quarter’s sales results were $6.58B. AMGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.93% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
Next quarter’s sales forecast for AMGN is $6.76B with a range of $6.63B to $6.91B. The previous quarter’s sales results were $6.58B. AMGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.93% of the time in the same period. In the last calendar year AMGN has Outperformed its overall industry.
AMGN Analyst Recommendation Trends
In the current month, AMGN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AMGN average analyst price target in the past 3 months is $259.57
In the current month, AMGN has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AMGN average analyst price target in the past 3 months is $259.57

AMGN Stock Forecast FAQ

What is AMGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is $259.57.
    What is AMGN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for AMGN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is AMGN a Buy, Sell or Hold?
        Amgen has a conensus rating of Hold which is based on 4 buy ratings, 7 hold ratings and 4 sell ratings.
          What is Amgen’s price target?
          The average price target for Amgen is $259.57. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $325.00 ,the lowest forecast is $185.00. The average price target represents -9.37% Decrease from the current price of $286.4.
            What do analysts say about Amgen?
            Amgen’s analyst rating consensus is a ‘Hold. This is based on the ratings of 15 Wall Streets Analysts.

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis